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followed by successful engraftment. Grade 2 nausea and grade 1
emesis were seen brieﬂy on day 2 of TMI. Skin erythema, oral
mucositis, esophagitis, and enteritis were not observed. Conclu-
sions:This report demonstrates the feasibility to selectively deliver
myeloablative doses of radiation to bone and marrow using To-
motherapy. Organ doses were substantially lower than those asso-
ciated with standard TBI and predict for the potential to signiﬁ-
cantly reduce associated toxicities, allowing for dose escalation.
Ongoing trials will deﬁne the maximum TMI/TMLI doses achiev-
able and deﬁne the potential advantages and limitations of this new
approach for patients undergoing HSCT (Table1).
Median Organ Doses (Gy) for TMI 12 and 20 Gy vs Standard TBI
12 Gy in a 20 Year Old Patient with AML
Organ TMI 12 Gy TMI 20 Gy Standard TBI 12 Gy
Lungs 4.3 6.8 8.8
Esophagus 3.9 5.6 12.4
Liver 6.0 8.7 12.3
Kidneys 5.6 8.7 12.2
Bowel 3.5 5.0 12.3
Bladder 7.0 7.4 12.4
Eyes 6.6 7.0 11.3
Parotids 3.9 4.8 11.8
Oral cavity 2.2 3.0 11.8
Stomach 3.1 5.0 12.2
Ovaries 4.3 6.0 12.3
Breasts 6.9 8.7 11.5
Heart 6.2 6.4 12.1
Thyroid 3.7 4.9 12.1
Brain 4.0 7.9 12.0
Lens 1.5 1.9 11.3
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ABSOLUTE NUMBER OF TRANSPLANTED CD34 CELLS EXPRESSING
C-MPL (CD110) CORRELATES WITH SPEED OF PLATELET ENGRAFT-
MENT FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION
Sartor, M.M.1, Antonenas, V.2, Garvin, F.2, Bradstock, K.F.2,
Gottlieb, D.J.2 1. Flow Cytometry Unit, Westmead Hospital., Sydney,
NSW, Australia; 2. Sydney Cellular Therapies Laboratory, Westmead
Hospital, Sydney, NSW, Australia.
Recovery of neutrophil numbers after peripheral blood stem cell
transplantation (PBSCT) is closely associated with graft CD34
cell dose. Predicting the speed of platelet recovery is more difﬁcult
but would be of value given that a signiﬁcant minority of patients
experience delayed platelet recovery and bleeding complications
after transplantation. In this study we retrospectively analysed the
graft composition of 29 patients who underwent autologous trans-
plantation, using blood stem cells mobilized with cyclophoshamide
and G-CSF, to assess the utility of c-mpl expression on CD34
cells as a predictor of platelet engraftment (ie, time to platelet
count greater than 20  109/L for 3 consecutive days without the
need for platelet transfusion). Absolute CD34 cells and CD34
subsets expressing c-mpl were enumerated using a published single
platform viable CD34 ﬂow cytometry assay (BMT, 2005). Of the
29 patients 7 required at least 21 days for platelet engraftment.
These patients received a median graft dose of 5.7  104
CD34CD110 cells/kg compared with a median dose of 13.4 
104 cells/kg received by patients who experienced platelet engraft-
ment within 21 days of transplant (P .013). In contrast, there was
no difference in the number of CD34 cells/kg infused (4.0 v 4.9
106/kg for 	 or  21 days for platelet engraftment respectively,
P  .23). There was a poor correlation between the absolute
number of CD34 cells and the number of CD34CD110 cells
in the graft (r2  0.48). Similarly there was no correlation between
the percentage of CD34 cells expressing c-mpl and the speed of
platelet engraftment (8.1 v 5.8%) for 	 or  21 days for platelet
engraftment respectively, P  .39). Patients with 	21 days for
platelet engraftment received platelet transfusions more often than
those with 21 days for platelet engraftment (median 9 v 2 trans-
fusions, P  .001). The absolute number of CD34/CD110
cells/kg infused at time of transplantation appears to be an impor-
tant factor identifying patients at risk of delayed (	21 days) platelet
engraftment. Those with 6  104CD34/CD110cells/kg are at
particularly high risk of delayed platelet engraftment requiring
multiple transfusion after transplantation.
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AMD3100  G-CSF IMPROVES HEMATOPOIETIC PROGENITOR CELL
(HPC) COLLECTION IN PATIENTS WITH HODGKIN’S DISEASE (HD)
Cashen, A.F.1, Devine, S.1, Vij, R.1, DiPersio, J.1 Washington Uni-
versity School of Medicine, St. Louis, MO.
For patients undergoing autologous stem cell transplantation, the
number of CD34 cells infused is a reliable predictor of neutro-
phil and platelet engraftment, with doses 5  106 CD34
cells/kg associated with faster count recovery. However, among the
98 patients with HD who have undergone G-CSF-alone mobili-
zation at our institution in the past 5 years, 22% did not achieve a
minimum HPC collection of 2  106 CD34 cells/kg in 5
apheresis procedures, and only 15% achieved a collection 5 
106 CD34 cells/kg. AMD3100 mobilizes HPCs by reversibly
inhibiting the interaction of CXCR4 and SDF-1
. It has been
shown to improve HPC mobilization in patients with multiple
myeloma and non-Hodgkin’s lymphoma. Here we present results
for the ﬁrst ten HD patients treated with a mobilization regimen of
AMD3100  G-CSF. Ten patients with relapsed (8) or refractory
(2) HD were mobilized with G-CSF (10 ug/kg/day)  AMD3100
(240 ug/kg/day) beginning on day 4. Apheresis was performed 11
hours after each AMD3100 dose. The ﬁrst dose of AMD3100
produced a median (range) 3.0 (1.9–5.1)-fold increase in the num-
ber of circulating CD34 cells. Six patients achieved a collection
of 5  106 CD34 cells/kg, and all patients collected 	2  106
CD34 cells/kg (range, 3.6–9.4). The median (range) number of
apheresis procedures performed per patient was 2 (1–4). No grade
II-IV adverse events were ascribed to AMD3100. All patients have
been transplanted with G-CSF AMD3100 mobilized cells. They
have had prompt and stable engraftment, with median neutrophil
recovery at day9 (9–11) and median platelet recovery at day16
(12–23). We conclude that AMD3100G-CSF is a well-tolerated
and effective mobilization regimen in patients with HD. All pa-
tients (100%, 95% CI 69%–100%) mobilized with AMD3100 
G-CSF achieved the minimum collection of 2  106 CD34
cells/kg, and a signiﬁcantly higher proportion of patients (60%,
95% CI 26%–88%) achieved the goal collection of  5  106
CD34 cells/kg than did the historical controls (15%). Impor-
tantly, the median collection in the ﬁrst two days of pheresis was
5.4  106 CD34 cells/kg, which is signiﬁcantly better than
historical controls, who collected a median 3.0  106 CD34
cells/kg in the ﬁrst two days of pheresis (P  .014). Our results
demonstrate that the mobilization regimen of AMD3100  G-
CSF can improve the number of HPCs collected and decrease the
number of days of pheresis in HD patients.
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HEMATOPOIETIC AC133 STEM CELL THERAPY FOR PATIENTS WITH
SEVERE PERIPHERAL VASCULAR DISEASE
Statkute, L.1, Oyama, Y.1, Pearce, W.1, Yaung, K.1, Villa, M.1,
Shook, T.1, Clifton, R.1, Verda, L.1, Krosnjar, N.1, Burt, R.K.1 Division
of Immunotherapy, Department of Medicine, Northwestern University
Feinberg School of Medicine, Chicago, IL.
Hematopoietic stem cells, especially more primitive endothelial
cell precursors, AC133 cells, may contribute to neo-angiogene-
sis. Here we report short-term outcomes of the ﬁrst 5 patients who
underwent autologous selected AC133 stem cell percutaneous
transplant for their medically refractory and not-amenable to sur-
gical reconstruction lower extremity (LE) peripheral vascular dis-
ease (PVD). Patients were 3 females and 2 males; median age was
59 (range 26–84) years old. Peripheral blood AC133 cells were
mobilized with G-CSF 10 mcg/kg/day for 4 days. Median aphere-
sis number of was 1 (range 1 to 2). AC133 cells were enriched
using CliniMACS device, Miltenyi Biotec, Inc. Total number of
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injected AC133 stem cells in 4 patients was 38.2, 141, 170, 51.3
million, and 28 million of CD34 cells in 1 patient. Three patients
underwent percutaneous intramuscular AC133 stem cell trans-
plant into the right LE, 2 patients into the left LE. Injection sites
were marked by ultrasound and were 4 to 20 sites per extremity.
There were no complications associated with the procedure. Me-
dian follow-up after the transplant is 4 (range 1.5–11) months. First
patient with very advanced LE ischemia, unfortunately, was in-
volved into study too late as ischemia continued to progress and
eventually patient required a below-knee amputation. Second pa-
tient with Burger’s disease, now 7.5 months after the transplant,
has had signiﬁcant improvement in symptoms such as rest pain and
claudication. Objective testing at 3- and 6-month follow-up
showed improvement in all parameters, including detectable new
faint posterior tibialis (PT) artery pulse, improved four-meter and
six-minute walk tests, walking impairment questionnaire, Gardner
graded treadmill test, and Doppler arterial brachial index, dorsalis
pedis (DP), and PT values increasing from 0.34, 28, 37 to 0.37, 37,
43, respectively. Additionally, MRA of LE showed increasing num-
ber of collateral vessels in a diseased calf. Last 3 patients had a short
follow-up with no objective testing repeated, although all of them
reported marked symptom improvement and increased walking
capacity. In last 2 patients, we detected faint DP and PT pulses,
which were absent before procedure. Our preliminary data suggest
that AC133 stem cell percutaneous transplant can be performed
safely and appears to be beneﬁcial therapy for selected patients
with severe peripheral vascular disease.
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LEUKOCYTE AND PLATELET COUNTS CAN BE USED TO GUIDE COL-
LECTION OF AUTOLOGOUS STEM CELLS AFTER G-CSF MOBILIZATION
ON THE FIRST TWO DAYS OF LEUKAPHERESIS BUT NOT BEYOND
Gidron, A.1, Mehta, J.1 Division of Hematology/Oncology, Northwest-
ern University, Chicago, IL.
When donors are treated with G-CSF to collect stem cells for
allogeneic transplantation, the combination of a pre-apheresis leu-
kocyte count of 25  109/L anda pre-apheresis platelet count of
100  109/L is associated with excellent mobilization as mea-
sured by an absolute peripheral blood CD34 cell count
(PBCD34) of 20/L, and can be used to guide harvest timing
(Tomblyn et al Bone Marrow Transplantation advance online
publication 01 August 2005; doi: 10.1038/sj.bmt.1705117). We
wanted to see if this observation could be extended to patients
receiving 10–16 g/kg G-CSF daily as the sole mobilizing agent
for autologous stem cell collection. Data from 161 leukapheresis
procedures (65 day 1 collections, 47 day 2 collections, and 49
collections done beyond day 2) were analyzed to determine corre-
lation between pre-apheresis leukocytes, platelets, and PBCD34.
Overall, when leukocytes 25 and platelets 100, PBCD34 was
2.9–515.5 (median 31.8); signiﬁcantly (P  .0001) higher than
PBCD34 of 0.6–226.0 (median 6.0) when leukocytes were 25
and/or platelets were 100. Among day 1 collections, with leuko-
cytes 25 and platelets 100, PBCD34 was 20 and 10 in 63% and
78% of the time compared to 16% and 36% of the time if
leukocytes were 25 and/or platelets were 100 (P  .0001 and
P  .001, respectively). Similarly, PBCD34 levels of 20 and 10
were obtained 63% and 87% of the time with day 2 collections
when leukocytes were 25 and platelets 100, compared with
19% and 35% of the time when leukocytes were 25 and/or
platelets were100 (P .003 and 0.001, respectively). Beyond day
2, when leukocytes 25 and platelets 100, PBCD34 was 20 50%
of the time compared with 7% when leukocytes were 25 and/or
platelets were 100 (P  .047). Our data suggest that in patients
with hematologic malignancies receiving G-CSF for mobilization
of autologous stem cells, the combination of a leukocyte count of
25 and a platelet count of 100 is associated with excellent
mobilization of stem cells in the majority of patients on the ﬁrst
and second harvest days but not beyond. Conversely, lower leuko-
cyte and/or platelet counts predict for poor mobilization beyond
the second day, but not on the ﬁrst two days. Thus, on the ﬁrst and
second days of stem cell collection in patients mobilized with
G-CSF, apheresis can be initiated based on favorable hematologic
parameters without necessarily awaiting PBCD34 levels. However,
beyond the second day, PBCD34 levels should guide apheresis.
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SYNGENEIC NEUROBLASTOMA CELLS TRANSIENTLY-TRANSFECTED
WITH PLASMID DNA VECTORS ENCODING A PANEL OF IMMUNE STIM-
ULATORY MOLECULES CAN INDUCE ANTI-TUMOR IMMUNITY EARLY
AFTER BMT
Jing, W.1, Yan, X.1, Orentas, R.J.1, Johnson, B.D.1 Medical College of
Wisconsin, Milwaukee, WI.
Mouse neuroblastoma (Neuro-2a) cells genetically modiﬁed to
express CD54 (ICAM-1), CD80, CD86, and CD137L (4-1BB
ligand) can serve as a tumor vaccine. The goals of this study were
to determine the cellular components required to induce tumor-
protective immunity with this vaccine early after syngeneic bone
marrow transplantation (BMT), and to determine if the cell-based
vaccine could prevent tumor growth in a minimal residual disease
model. Lethally irradiated A/J mice were transplanted with synge-
neic BM cells with or without puriﬁed T cells or splenocytes (as a
source of T cells). The Neuro-2a-based vaccine was given to
transplant recipients on days 7 and 14 post-transplant. Vaccination
of mice given BM without added T cells failed to protect mice from
a challenge of 105 or 106 viable tumor cells. In contrast, 79% of
vaccinated mice given T cells at the time of BMT survived tumor
challenge. Development of protective immunity was dependent
upon both CD4 and CD8 T cells. We concluded that the
adoptive transfer of T cells was absolutely required for induction of
tumor vaccine-induced protective immunity. We examined
whether depletion of CD25 regulatory T cells from the adop-
tively-transferred T cells or in vivo CD25 depletion of the trans-
plant recipients would further increase vaccine-induced tumor im-
munity, but they did not. This suggests that the lethal conditioning
itself had eliminated the majority of CD25 regulatory T cells. To
more closely mimic treatment of “minimal” residual disease, A/J
mice transplanted with BM and splenocytes were inoculated with
104 AGN2a cells one day after BMT. Tumor vaccination was
administered on days 2 and 9 post-BMT. Tumor vaccination in
this model failed to protect mice from tumor progression. How-
ever, in a preliminary experiment, post-BMT vaccination with
tumor cells expressing CD54, CD80, CD86, CD137L, and IL-15
could prevent tumor progression if splenocytes given at the time of
BMT were from tumor-primed donors. Collectively, these results
demonstrate that anti-neuroblastoma immunity can be induced
early after BMT using novel cell-based cancer vaccines; however,
in a setting of minimal residual disease, a combination of adoptive
immunotherapy and tumor vaccination is required to prevent post-
transplant tumor relapse.
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MITOXANTRONE AND MELPHALAN AS A CONDITIONING REGIMEN FOR
AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN
ADULTS WITH ACUTE MYELOGENOUS LEUKEMIA
Sprague, K.A.1, Padgaonkar, V.A.1, Klein, A.K.1, Chan, G.W.1,
Miller, K.B.2, Klingemann, H.1 1. Tufts-New England Medical Center,
Boston, MA; 2. Beth Israel-Deaconess Medical Center, Boston, MA.
A variety of conditioning regimens are used for autologous he-
matopoietic stem cell transplantation in patients with acute my-
elogenous leukemia (AML). High dose mitoxantrone and melpha-
lan (Mito/Mel) has been reported as an effective and well-tolerated
regimen for autologous peripheral blood stem cell transplantation
(APBSCT) in patients with lymphoma. We review our experience
with Mito/Mel as a conditioning regimen in 18 adult patients (12
female, 6 male) with intermediate or high risk AML who under-
went APBSCT. All patients received anthracycline based induction
and consolidation chemotherapy prior to APBSCT. At the time of
transplantation, 16 patients were in ﬁrst complete remission (CR)
and 2 patients were in second CR. Median age at the time of
APBSCT was 51 years (range 19–70). All patients received a
conditioning regimen consisting of mitoxantrone 60 mg/m2 IV on
day 4 and melphalan 180 mg/m2 IV on day 1, followed by
infusion of autologous peripheral blood stem cells on day 0. Rapid
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